End Stage Renal Disease on Dialysis Clinical Trial
Official title:
Short-Term Effects of Therapeutic Diet in Dialysis Patients
Verified date | March 2022 |
Source | Far Eastern Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with end-stage kidney disease have hyperphosphatemia and accumulated uremic toxin level due to decreased urine excretion ability. Unhealthy diet causes altered mineral metabolism, elevated uremic toxin level, immune dysregulation, and inflammation. The investigators hypothesize that therapeutic diet intervention reverses altered mineral metabolism, elevated uremic toxin level, immune dysregulation, and inflammation. In this study, the investigators crafted 7-day special healthy diet to illustrate the clinical implications of therapeutic diet for dialysis patients.
Status | Completed |
Enrollment | 32 |
Est. completion date | March 1, 2022 |
Est. primary completion date | December 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 99 Years |
Eligibility | Inclusion Criteria: - Subjects with aged older than 20 years, ESKD undergoing maintenance dialysis for more than three months, having adequate dialysis, serum intact parathyroid hormone less than 800 pg/mL and good dietary compliance Exclusion Criteria: - Patients who meet any of the following criteria will be excluded from the study: 1. Serum albumin level less than 2.5 g/dL 2. Hospitalization within the past 4 weeks 3. Prebiotics, probiotics, symbiotics or antibiotics use within the past 4 weeks 4. History of psychiatric disorders 5. Having mental retardation 6. Those who dislike of the study meals 7. Soft diet requirement 8. Vegetarian |
Country | Name | City | State |
---|---|---|---|
Taiwan | Far Eastern Memorial Hospital | New Taipei City |
Lead Sponsor | Collaborator |
---|---|
Far Eastern Memorial Hospital |
Taiwan,
Tsai WC, Wu HY, Peng YS, Hsu SP, Chiu YL, Chen HY, Yang JY, Ko MJ, Pai MF, Tu YK, Hung KY, Chien KL. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018 Nov 1;33(11):1977-1983. doi: 10.1093/ndt/gfy005. — View Citation
Tsai WC, Wu HY, Peng YS, Hsu SP, Chiu YL, Yang JY, Chen HY, Pai MF, Lin WY, Hung KY, Chu FY, Tsai SM, Chien KL. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial. Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1475-1483. doi: 10.2215/CJN.04250419. Epub 2019 Sep 13. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Concentrations of intact fibroblast growth factor 23 (pg/mL) | Difference in change-from-baseline intact fibroblast growth factor 23 (pg/mL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of C-terminal fibroblast growth factor 23 (RU/mL) | Difference in change-from-baseline C-terminal fibroblast growth factor 23 (RU/mL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of phosphate (mg/dL) | Difference in change-from-baseline phosphate (mg/dL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of calcium (mg/dL) | Difference in change-from-baseline calcium (mg/dL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of intact parathyroid hormone (pg/mL) | Difference in change-from-baseline intact parathyroid hormone (pg/mL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of free indoxyl sulfate (mg/L) | Difference in change-from-baseline free indoxyl sulfate (mg/L) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of free p-cresol sulfate (mg/L) | Difference in change-from-baseline free p-cresol sulfate (mg/L) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of pre-albumin (g/dL) | Difference in change-from-baseline pre-albumin (g/dL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of albumin (g/dL) | Difference in change-from-baseline albumin (g/dL) between therapeutic diet and usual diet | 7 days | |
Secondary | Concentrations of C-reactive protein (mg/dL) | Difference in change-from-baseline C-reactive protein (mg/dL) between therapeutic diet and usual diet | 7 days | |
Secondary | Absolute number (per µl blood) of CD4+ (cluster of differentiation 4) T cells | Difference in change-from-baseline absolute number (per µl blood) of CD4+ T cells between therapeutic diet and usual diet | 7 days | |
Secondary | Absolute number (per µl blood) of CD8+ (cluster of differentiation 8) T cells | Difference in change-from-baseline absolute number (per µl blood) of CD8+ T cells between therapeutic diet and usual diet | 7 days | |
Secondary | Absolute number (per µl blood) of monocytes | Difference in change-from-baseline absolute number (per µl blood) of monocytes between therapeutic diet and usual diet | 7 days | |
Secondary | Percentage (%) of CD4+ (cluster of differentiation 4) T cells | Difference in change-from-baseline percentage (%) of CD4+ (cluster of differentiation 4) T cells between therapeutic diet and usual diet | 7 days | |
Secondary | Percentage (%) of CD8+ (cluster of differentiation 8) T cells | Difference in change-from-baseline percentage (%) of CD8+ (cluster of differentiation 8) T cells between therapeutic diet and usual diet | 7 days | |
Secondary | Percentage (%) of monocytes | Difference in change-from-baseline percentage (%) of monocytes between therapeutic diet and usual diet | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05978479 -
The Effect of Individualized Education Using the Teach-Back Method Treatment on Treatment Adherence and the Coping Skills
|
N/A | |
Completed |
NCT06022835 -
Chlorhexidine Gluconate-gel Dressing for Exit Site Infection in Peritoneal Dialysis
|
N/A | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Recruiting |
NCT04046042 -
Virtual Reality Intradialysis: Last vs. First Part of the Session
|
N/A | |
Not yet recruiting |
NCT04527640 -
Effects of Synbiotics Supplementation on the Uremic Toxin Indoxyl Sulfate Level and Constipation in End-stage Renal Disease Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT05947708 -
The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300
|
N/A | |
Recruiting |
NCT05735743 -
MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence
|
N/A | |
Active, not recruiting |
NCT04546958 -
Nutritional Interventions in Peritoneal Dialysis Patients With Hypoalbuminemia
|
N/A | |
Recruiting |
NCT04286477 -
The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT
|
||
Completed |
NCT04487301 -
A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease
|
||
Recruiting |
NCT05677555 -
Colchicine and Inflammation in Hemodialysis Patients
|
Phase 2 | |
Completed |
NCT04789876 -
Effectiveness of The Phosphate Mobile App on Serum Phosphorus in Adult Hemodialysis Patients With Hyperphosphatemia
|
N/A | |
Completed |
NCT04125537 -
Pathways Project: Kidney Supportive Care
|
||
Suspended |
NCT05915286 -
Diuretic Use in Hemodialysis Patients With Residual Renal Function
|
Phase 4 | |
Completed |
NCT04912050 -
EXtension of Tablo TrEatmeNt Duration Registry
|
||
Recruiting |
NCT04360694 -
RandomizEd ClinicAL triaL on the Efficacy and saFety of Incremental Hemodialysis (REAL-LIFE)
|
N/A | |
Recruiting |
NCT04501159 -
pH, Hypoxia and Haemodialysis
|
||
Recruiting |
NCT05032651 -
Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients
|
N/A | |
Completed |
NCT04806126 -
Evaluation of a Virtual Home Dialysis Mentoring Program (Home)
|
||
Recruiting |
NCT05671991 -
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
|
Phase 4 |